Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.
Saved in:
| Title: | Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia. |
|---|---|
| Authors: | Sun H; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA., Liu S; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Liu X; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Tsakmaklis N; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Hatcher JM; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Guerrera ML; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Kofides A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Ramirez-Gamero A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Peachey AL; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.; Department of Computer Science, Metropolitan College, Boston University, Boston, MA.; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark., Chea V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Kim N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Lyu H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Lu W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Livak KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Meid K; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Guijosa A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Flynn CA; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Pizzarella D; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Patterson CJ; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Hao M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Yuan W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Branagan AR; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Sarosiek SR; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Castillo JJ; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Hunter ZR; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Treon SP; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA. |
| Source: | Blood [Blood] 2026 May 14; Vol. 147 (20), pp. 2298-2314. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41671559 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Sun+H%22">Sun H</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Sklavenitis-Pistofidis+R%22">Sklavenitis-Pistofidis R</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Liu+S%22">Liu S</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Liu+X%22">Liu X</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Tsakmaklis+N%22">Tsakmaklis N</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Hatcher+JM%22">Hatcher JM</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Guerrera+ML%22">Guerrera ML</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Kofides+A%22">Kofides A</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ramirez-Gamero+A%22">Ramirez-Gamero A</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Peachey+AL%22">Peachey AL</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Keskin+DB%22">Keskin DB</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.; Department of Computer Science, Metropolitan College, Boston University, Boston, MA.; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.<br /><searchLink fieldCode="AU" term="%22Chea+V%22">Chea V</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Kim+N%22">Kim N</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Lyu+H%22">Lyu H</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Lu+W%22">Lu W</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Livak+KJ%22">Livak KJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Meid+K%22">Meid K</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Guijosa+A%22">Guijosa A</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Flynn+CA%22">Flynn CA</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Pizzarella+D%22">Pizzarella D</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Patterson+CJ%22">Patterson CJ</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Hao+M%22">Hao M</searchLink>; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Yi+S%22">Yi S</searchLink>; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Yuan+W%22">Yuan W</searchLink>; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Branagan+AR%22">Branagan AR</searchLink>; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wu+CJ%22">Wu CJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ghobrial+IM%22">Ghobrial IM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Qiu+L%22">Qiu L</searchLink>; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Sarosiek+SR%22">Sarosiek SR</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Castillo+JJ%22">Castillo JJ</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Hunter+ZR%22">Hunter ZR</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Treon+SP%22">Treon SP</searchLink>; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227603509%22">Blood</searchLink> [Blood] 2026 May 14; Vol. 147 (20), pp. 2298-2314. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7603509 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1528-0020 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200064971%22">00064971 </searchLink><i>NLM ISO Abbreviation: </i>Blood <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41671559 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1182/blood.2025032268 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2298 Titles: – TitleFull: Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Sun H – PersonEntity: Name: NameFull: Sklavenitis-Pistofidis R – PersonEntity: Name: NameFull: Liu S – PersonEntity: Name: NameFull: Liu X – PersonEntity: Name: NameFull: Tsakmaklis N – PersonEntity: Name: NameFull: Hatcher JM – PersonEntity: Name: NameFull: Guerrera ML – PersonEntity: Name: NameFull: Kofides A – PersonEntity: Name: NameFull: Ramirez-Gamero A – PersonEntity: Name: NameFull: Peachey AL – PersonEntity: Name: NameFull: Li S – PersonEntity: Name: NameFull: Keskin DB – PersonEntity: Name: NameFull: Chea V – PersonEntity: Name: NameFull: Kim N – PersonEntity: Name: NameFull: Lyu H – PersonEntity: Name: NameFull: Lu W – PersonEntity: Name: NameFull: Livak KJ – PersonEntity: Name: NameFull: Meid K – PersonEntity: Name: NameFull: Guijosa A – PersonEntity: Name: NameFull: Flynn CA – PersonEntity: Name: NameFull: Pizzarella D – PersonEntity: Name: NameFull: Patterson CJ – PersonEntity: Name: NameFull: Hao M – PersonEntity: Name: NameFull: Yi S – PersonEntity: Name: NameFull: Yuan W – PersonEntity: Name: NameFull: Branagan AR – PersonEntity: Name: NameFull: Wu CJ – PersonEntity: Name: NameFull: Ghobrial IM – PersonEntity: Name: NameFull: Qiu L – PersonEntity: Name: NameFull: Sarosiek SR – PersonEntity: Name: NameFull: Castillo JJ – PersonEntity: Name: NameFull: Hunter ZR – PersonEntity: Name: NameFull: Treon SP IsPartOfRelationships: – BibEntity: Dates: – D: 14 M: 05 Text: 2026 May 14 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1528-0020 Numbering: – Type: volume Value: 147 – Type: issue Value: 20 Titles: – TitleFull: Blood Type: main |
| ResultId | 1 |
